Ozempic Proves 1 Breakthrough Is All You Need

Here’s how Novo Nordisk stock rates… [Turn Your Images On] Editor’s note: U.S. markets are closed for Labor Day. But that’s not stopping Matt from writing about “Bullish” stocks. Read on to see how Ozempic’s fat-burning side effect has created a massive tailwind for the pharmaceutical company behind it. --------------------------------------------------------------- [Ozempic Proves 1 Breakthrough Is All You Need]( - Pharmaceutical companies just need one big break. - One Danish company’s fat-burning pill has created a boom. - And its stock rates “Bullish” in Green Zone Power Ratings. [Turn Your Images On] [Matt Clark, Chief Research Analyst]( The pharmaceutical industry runs on razor-thin margins. One drug can make or break an entire company. Take Aradigm for example. The California-based biotech company was in business for nearly 30 years before one drug spelled its demise. The company spent millions developing a respiratory drug delivery system to treat chronic lung infections. However, the Food and Drug Administration rejected the treatment and requested additional study. Aradigm only had about $7 million in cash — not nearly enough to run more research. By February 2019, the company filed for Chapter 11 bankruptcy. Aradigm is a cautionary tale that every pharmaceutical company doesn’t want to repeat. Today, I’m going to tell you about one company making big headlines … and big money with just one drug. I’ll share what Adam O’Dell’s Green Zone Power Ratings system tells us about its future prospects. --------------------------------------------------------------- [Turn Your Images On]( [See How to Claim Your FREE COPY Now: Endless Income: 50 Secrets to a Happier, Richer Life]( See how to get 3X more dividend income than usual with a few nearly forgotten “high-class” stocks … find out how to become a “lazy landlord” and collect income without owning real estate … discover three simple words that can put 40% more money in your pocket for retirement … and much, much more. The wealthy have been using secrets like these for decades … and now you can too. [Click here and see how to claim your free copy now.]( --------------------------------------------------------------- The Short Road to Weight Loss We’ve all looked in the mirror and thought we could lose a few pounds. For most of us, that means eating healthy and trying out that new gym down the street. But others seek out a much easier road … pills or shots that come with a promise of a beach body in no time. Danish pharmaceutical company Novo Nordisk A/S (NYSE: NVO) and its drug Ozempic has made headlines for helping people [lose weight]( [Turn Your Images On] It’s important to note that Ozempic wasn’t created for weight loss… It’s a drug to treat diabetes. But Ozempic’s tie to weight loss has generated big profits for Novo Nordisk. So much so that it’s close to becoming the most valuable company by market cap in Europe: [Turn Your Images On] [(Click here to view larger image.)]( Novo Nordisk (the black line in the chart above) is fast approaching Louis Vuitton’s (LVMHF) $423 billion valuation. It’s grown so much that its $419 billion market cap is [greater than Denmark’s entire gross domestic product](. As a result, Novo Nordisk has brought a massive influx of capital into the Danish economy, forcing Denmark’s central bank to keep interest rates low — an impressive feat in 2023. --------------------------------------------------------------- [Turn Your Images On]( From our Partners at Banyan Hill Publishing. [Kicking Yourself for Missing Out on Bitcoin?]( Don’t worry. One expert is saying another coin has 20X the potential of bitcoin. And with cryptos heating up, it could be the [perfect time to get in](. --------------------------------------------------------------- NVO and Its Green Zone Power Ratings NVO rates 76 out of 100 on our proprietary Green Zone Power Ratings system. That means we are “Bullish” on the stock and expect it to outperform the market by 2X over the next 12 months. [Turn Your Images On] [(Click here to view larger image.)]( While the stock’s 22% runup since mid-July has blown its price-to-earnings and price-to-cash flow ratios up — it rates a 5 on our Value metric— its Growth and Quality remain impressive. In its recent earnings statement, Novo Nordisk reported a 29% increase in sales for the first six months of 2023. NVO’s North American sales jumped 45% alone — leading to an 80 rating on Growth. The company’s operating profit increased 30%, while its returns on assets, equity and investment are leaps and bounds above the system-specific biopharmaceutical industry averages. Bonus: NVO has a 1.09% forward dividend yield, paying shareholders $2.06 per year for every share they own. Bottom line: One drug can make or break a pharmaceutical company. There are plenty of cautionary tales of companies that failed because they couldn’t get a drug approved or marketed properly. But Novo Nordisk has found a niche with Ozempic … and that niche is turning over billions in profit for the company. That’s a compelling reason why you should look at NVO for your portfolio. Until next time… Safe trading, [Matt Clark signature] Matt Clark, CMSA® Chief Research Analyst, Money & Markets --------------------------------------------------------------- Check Out More From Stock Power Daily: - [THE ONLY POT STOCK (MAYBE) WORTH BUYING]( - [DON’T CHASE THIS RAGS TO RICHES EV RALLY]( - [90 YEARS LATER, 1 HYBRID INVESTMENT STILL WORKS]( Privacy Policy The Money & Markets, P.O. Box 8378, Delray Beach, FL 33482. To ensure that you receive future issues of Money & Markets, please add info@mb.moneyandmarkets.com to your address book or [whitelist]( within your spam settings. For customer service questions or issues, please contact us for assistance. The mailbox associated with this email address is not monitored, so please do not reply. Your feedback is very important to us so if you would like to contact us with a question or comment, please click here: [( Legal Notice: This work is based on what we've learned as financial journalists. It may contain errors and you should not base investment decisions solely on what you read here. It's your money and your responsibility. Nothing herein should be considered personalized investment advice. Although our employees may answer general customer service questions, they are not licensed to address your particular investment situation. Our track record is based on hypothetical results and may not reflect the same results as actual trades. Likewise, past performance is no guarantee of future returns. Certain investments carry large potential rewards but also large potential risk. Don't trade in these markets with money you can't afford to lose. Money & Markets permits editors of a publication to recommend a security to subscribers that they own themselves. However, in no circumstance may an editor sell a security before our subscribers have a fair opportunity to exit. Any exit after a buy recommendation is made and prior to issuing a sell notification is forbidden. The length of time an editor must wait after subscribers have been advised to exit a play depends on the type of publication. (c) 2023 Money & Markets, LLC. All Rights Reserved. Protected by copyright laws of the United States and treaties. This Newsletter may only be used pursuant to the subscription agreement. Any reproduction, copying, or redistribution, (electronic or otherwise) in whole or in part, is strictly prohibited without the express written permission of Money & Markets. P.O. Box 8378, Delray Beach, FL 33482. (TEL: 800-684-8471) Remove your email from this list: [Click here to Unsubscribe](